亞太精準醫療迎來新里程碑！攜手泰國 NCI 簽署 戰略合作文件，全面佈局東協精準醫療藍圖

亞太精準醫療迎來重大突破 ！我們醫華生技（CytoAurora）於 2026 年 7 月 2 日正式與泰國公共衛生部醫療服務署國家癌症研究所（NCI）簽署戰略合作文件。雙方將針對癌症醫療創新展開深度共同研發，同日舉辦高規格國際學術研討會，正式宣告將國際尖端生技全面導入泰國醫療體系 。

💡 合作核心亮點：

頂尖技術全面引進：全面導入數位病理診斷、全幅切片成像（WSI）系統、特異性免疫圖譜分析及 iPSC 細胞治療技術。

無創早期癌症篩檢：核心 CTC 技術僅需「微量抽血」即可進行早期篩檢與即時療效監測，免除侵入性切片創傷。

亞太跨境協同發力：邀請吉田信介博士與周輝政教授進行深度分享，實質助推泰國邁向東協醫療與生物科技中心的戰略目標。

未來，醫華生技將持續以科技創新為核心並深化技術研發，推動精準醫療的實際應用，打造從細胞層面到臨床應用的完整閉環生態系 ；我們將全面加速在東南亞的精準醫療佈局 ，實質助推泰國邁向東協醫療與生物科技中心 ，攜手開啟精準醫療與癌症防治的新紀元 ，讓台灣自主研發的醫療科技在國際舞台上持續被看見！

A Major Breakthrough in Precision Medicine in the Asia-Pacific Region! On July 2, 2026, CytoAurora officially signed a Strategic Cooperation Agreement with the National Cancer Institute (NCI) under the Department of Medical Services of Thailand’s Ministry of Public Health. The two parties will engage in in-depth joint research and development focused on cancer treatment innovation. A high-profile international academic symposium was held on the same day to formally announce the comprehensive integration of cutting-edge international biotechnology into Thailand’s healthcare system.

💡 Key Highlights of the Collaboration:

1. Comprehensive Introduction of Cutting-Edge Technologies: Full integration of digital pathology diagnostics, whole-slide imaging (WSI) systems, specific immunoprofiling analysis, and iPSC cell therapy technologies.

2. Non-invasive early-stage cancer screening: Core CTC technology enables early screening and real-time treatment efficacy monitoring with just a “small blood sample,” eliminating the need for invasive biopsies.

3. Cross-border collaboration in the Asia-Pacific region: Dr. Shinsuke Yoshida and Professor Zhou Huizheng were invited to deliver in-depth presentations, providing substantial support for Thailand’s strategic goal of becoming the ASEAN hub for healthcare and biotechnology.

Moving forward, We will continue to prioritize technological innovation and deepen R&D efforts to advance the practical application of precision medicine, building a complete, closed-loop ecosystem spanning from the cellular level to clinical applications; We will comprehensively accelerate our precision medicine initiatives in Southeast Asia, substantially advancing Thailand’s strategic goal of becoming the ASEAN hub for healthcare and biotechnology. Together, we will usher in a new era of precision medicine and cancer prevention, ensuring that Taiwan’s independently developed medical technologies continue to gain recognition on the international stage!